28524099|t|Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI -Based Volumetric Analysis for Noninvasive Assessmen t of Temozolomide Treatment
28524099|a|Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM using semi-supervised source extraction and single-slice Magnetic Resonance Spectroscopic Imaging (MRSI). Nevertheless, GBMs are heterogeneous and single-slice studies could prevent obtaining relevant information. The purpose of this work was to evaluate whether a multi-slice MRSI approach, acquiring consecutive grids across the tumor, is feasible for preclinical models and may produce additional insight into therapy response. Nosological images were analyzed pixel-by-pixel and a relative responding volume, the Tumor Responding Index (TRI), was defined to quantify response. Heterogeneous response levels were observed and treated animals were ascribed to three arbitrary predefined groups: high response (HR, n = 2), TRI = 68.2 ± 2.8%, intermediate response (IR, n = 6), TRI = 41.1 ± 4.2% and low response (LR, n = 2), TRI = 13.4 ± 14.3%, producing therapy response categorization which had not been fully registered in single-slice studies. Results agreed with the multi-slice approach being feasible and producing an inverse correlation between TRI and Ki67 immunostaining. Additionally, ca. 7-day oscillations of TRI were observed, suggesting that host immune system activation in response to treatment could contribute to the responding patterns detected.
28524099	0	12	Metabolomics	T091	C1328813
28524099	16	23	Therapy	T061	C0087111
28524099	24	32	Response	T032	C0871261
28524099	36	47	Preclinical	T080	C1709630
28524099	48	60	Glioblastoma	T191	C0017636
28524099	64	80	Multi-Slice MRSI	T060	C1522706
28524099	88	107	Volumetric Analysis	T059	C3825502
28524099	112	133	Noninvasive Assessmen	T060	C0259832
28524099	139	151	Temozolomide	T109,T121	C0076080
28524099	152	161	Treatment	T061	C0087111
28524099	162	174	Glioblastoma	T191	C0017636
28524099	176	179	GBM	T191	C0017636
28524099	200	210	aggressive	T079	C0580822
28524099	219	230	brain tumor	T191	C0006118
28524099	234	240	adults	T100	C0001675
28524099	255	268	survival time	T201	C2919552
28524099	280	290	aggressive	T079	C0580822
28524099	291	298	therapy	T061	C0087111
28524099	300	312	Non-invasive	T169	C0205303
28524099	313	322	surrogate	T080	C0086589
28524099	323	333	biomarkers	T123	C0041366
28524099	337	344	therapy	T061	C0087111
28524099	345	353	response	T032	C0871261
28524099	361	369	relevant	T080	C2347946
28524099	374	383	improving	T080	C1272745
28524099	384	391	patient	T101	C0030705
28524099	392	400	survival	T052	C0038952
28524099	411	415	work	T062	C0008972
28524099	430	440	biomarkers	T123	C0041366
28524099	444	455	preclinical	T080	C1709630
28524099	456	459	GBM	T191	C0017636
28524099	466	499	semi-supervised source extraction	T059	C0005567
28524099	504	557	single-slice Magnetic Resonance Spectroscopic Imaging	T060	C1522706
28524099	559	563	MRSI	T060	C1522706
28524099	580	584	GBMs	T191	C0017636
28524099	589	602	heterogeneous	T080	C0019409
28524099	607	627	single-slice studies	T062	C0008972
28524099	652	660	relevant	T080	C2347946
28524099	661	672	information	T078	C1533716
28524099	678	685	purpose	T169	C1285529
28524099	694	698	work	T062	C0008972
28524099	706	714	evaluate	T062	C0936012
28524099	725	741	multi-slice MRSI	T060	C1522706
28524099	791	796	tumor	T191	C0027651
28524099	814	832	preclinical models	T170	C1514292
28524099	873	880	therapy	T061	C0087111
28524099	881	889	response	T032	C0871261
28524099	891	902	Nosological	T170	C0683326
28524099	915	923	analyzed	T062	C0936012
28524099	965	971	volume	T081	C0449468
28524099	977	999	Tumor Responding Index	T170	C0918012
28524099	1001	1004	TRI	T170	C0918012
28524099	1022	1030	quantify	T081	C1709793
28524099	1031	1039	response	T032	C0871261
28524099	1041	1054	Heterogeneous	T080	C0019409
28524099	1055	1063	response	T032	C0871261
28524099	1076	1084	observed	T169	C1441672
28524099	1089	1096	treated	T061	C0332293
28524099	1097	1104	animals	T008	C0003062
28524099	1128	1137	arbitrary	T080	C1264693
28524099	1149	1155	groups	T078	C0441833
28524099	1157	1170	high response	T032	C0871261
28524099	1172	1174	HR	T032	C0871261
28524099	1184	1187	TRI	T170	C0918012
28524099	1203	1224	intermediate response	T032	C0871261
28524099	1226	1228	IR	T032	C0871261
28524099	1238	1241	TRI	T170	C0918012
28524099	1260	1272	low response	T032	C0871261
28524099	1274	1276	LR	T032	C0871261
28524099	1286	1289	TRI	T170	C0918012
28524099	1316	1323	therapy	T061	C0087111
28524099	1324	1332	response	T032	C0871261
28524099	1333	1347	categorization	T185	C0008902
28524099	1387	1407	single-slice studies	T062	C0008972
28524099	1433	1453	multi-slice approach	T060	C1522706
28524099	1514	1517	TRI	T170	C0918012
28524099	1522	1541	Ki67 immunostaining	T059	C4055454
28524099	1557	1559	ca	T121,T123,T196	C0006675
28524099	1561	1566	7-day	T079	C0439228
28524099	1567	1579	oscillations	T061	C0695434
28524099	1583	1586	TRI	T170	C0918012
28524099	1592	1600	observed	T169	C1441672
28524099	1623	1647	immune system activation	T039	C2256029
28524099	1651	1672	response to treatment	T201	C0521982
28524099	1708	1716	patterns	T082	C0449774